💰 The proposal aligns Medicaid and Medicare reimbursement plans for cell and gene therapy for sickle cell disease.
🏥 The plan calls for increasing the payment to 75% of the cost of gene therapy, up from the current 65%.
🩺 The proposal and the Cell & Gene Therapy Access Model aim to provide a practical reimbursement strategy for ultra-expensive therapies.
💡 The models focus on outcomes and may lead to transparency and cost-effectiveness improvements in the reimbursement process.
Introduction:
The Centers for Medicare & Medicaid Services (CMS) has proposed increasing the New Technology Add-on Payment (NTAP) for cell and gene therapies for Medicare. This aligns with the recently announced Cell & Gene Therapy Access Model for Medicaid, creating a consistent reimbursement strategy for these therapies. This article discusses the proposed reimbursement changes, the challenges in reimbursing cell and gene therapies, and the potential impact of the new reimbursement model.
- The CMS has proposed increasing the payment for cell and gene therapies for Medicare from 65% to 75% of the therapy’s cost.
- This increased payment is only applicable during the therapy’s “newness period,” after which reimbursement returns to usual levels.
- The reimbursement proposal focuses on sickle cell disease patients initially, aiming to address the high treatment costs of recently approved therapies Casgevy and Lyfgenia.
- The reimbursement strategy is part of the larger CGT Access Model and aligns with President Biden’s efforts to lower prescription drug costs.
- The success of the proposed reimbursement model depends on measuring outcomes, managing data, and addressing challenges related to insurance portability and transparency.
Conclusion:
The proposed reimbursement changes for cell and gene therapies in Medicare align with the CGT Access Model for Medicaid, creating a consistent approach to reimbursing these therapies. This model addresses the high treatment costs of certain diseases and aims to improve accessibility and affordability. If successful, the model may be extended to cover other rare diseases and could also guide commercial insurers in developing similar reimbursement strategies. The proposed changes are seen as a step towards a practical reimbursement strategy for expensive cell and gene therapies, providing hope for patients in need of these therapies.
